| abstract |
The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdrl) as an agent for treating cancer. More particularly, it relates to an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdrl for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdrl is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdrl recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdrl and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer. |